title: The effect of the TLR9 ligand CpG-oligodeoxynucleotide on the protective immune response to alcelaphine herpesvirus-1-mediated malignant catarrhal fever in cattle.
abstract: We wished to determine the effect of of CpG ODN adjuvant on the magnitude and duration of protective immunity against alcelaphine herpesvirus-1 (AlHV-1) malignant catarrhal fever (MCF), a fatal lymphoproliferative disease of cattle. Immunity was associated with a mucosal barrier of virus-neutralising antibody. The results showed that CpG ODN included either with emulsigen adjuvant and attenuated AlHV-1 (atAlHV-1) or alone with atAlHV-1 did not affect the overall protection from clinical disease or duration of immunity achieved using emulsigen and atAlHV-1. This is in contrast to other similar studies in cattle with BoHV-1 or cattle and pigs with various other immunogens. In addition to this, several other novel observations were made, not reported previously. Firstly, we were able to statistically verify that vaccine protection against MCF was associated with virus-neutralising antibodies (nAbs) in nasal secretions but was not associated with antibodies in blood plasma, nor with total virus-specific antibody (tAb) titres in either nasal secretions or blood plasma. Furthermore, CpG ODN alone as adjuvant did not support the generation of virus-neutralising antibodies. Secondly, there was a significant boost in tAb in animals with MCF comparing titres before and after challenge. This was not seen with protected animals. Finally, there was a strong IFN-γ response in animals with emulsigen and atAlHV-1 immunisation, as measured by IFN-γ secreting PBMC in culture (and a lack of IL-4) that was not affected by the inclusion of CpG ODN. This suggests that nAbs at the oro-nasal-pharyngeal region are important in protection against AlHV-1 MCF.
authors.forename: Nevi
authors.initials: N
authors.lastname: Parameswaran
authors.forename: George C
authors.initials: GC
authors.lastname: Russell
authors.forename: Kathryn
authors.initials: K
authors.lastname: Bartley
authors.forename: Dawn M
authors.initials: DM
authors.lastname: Grant
authors.forename: David
authors.initials: D
authors.lastname: Deane
authors.forename: Helen
authors.initials: H
authors.lastname: Todd
authors.forename: Mark P
authors.initials: MP
authors.lastname: Dagleish
authors.affiliation: School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington, LE12 5RD Nottingham, UK. david.haig@nottingham.ac.uk.
authors.forename: David M
authors.initials: DM
authors.lastname: Haig
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis / Q000097:blood; D002417:Cattle; D002418:Cattle Diseases / Q000276:immunology* / Q000821:virology; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D018142:Gammaherpesvirinae / Q000276:immunology* / Q000502:physiology; D006566:Herpesviridae Infections / Q000276:immunology / Q000662:veterinary* / Q000821:virology; D007110:Immunity, Active / Q000187:drug effects; D008297:Male; D008304:Malignant Catarrh / Q000276:immunology* / Q000821:virology; D008745:Methylation; D009666:Nose / Q000821:virology; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage* / Q000737:chemistry; D051217:Toll-Like Receptor 9 / Q000819:agonists; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D051217:Toll-Like Receptor 9; D014613:Vaccines, Attenuated; D014765:Viral Vaccines